Ocupres-E, eye drops 0.25% 5 ml

Timolol is a non-selective beta-adrenoreceptor blocker. It has no membrane stabilizing or sympathomimetic activity. It affects both elevated intraocular pressure and normal pressure by reducing the amount of aqueous humor through its production. It begins to act one-third of an hour after instillation and continues for 24 hours. The maximum effect is observed after 1-2 hours.

Injection the drug is quickly absorbed into the eyeball. The systemic effect is minimal and occurs by absorption of Timolol through the conjunctiva, nasal mucosa, tear ducts.

Pharmacokinetics

In local administration it quickly penetrates through cornea, in small amount it enters systemic bloodstream due to absorption through conjunctival vessels, nasal mucosa and lacrimal tract.

Indications

Intraocular hypertension.
Open angle glaucoma.
Secondary glaucoma, including aphakic.
In combination with miotics for angle-closure glaucoma.
In case of congenital glaucoma.

Pharmacological effect

Timolol is a non-selective beta-adrenergic receptor blocker. It has no membrane stabilizing or sympathomimetic activity. It affects both increased intraocular pressure and normal pressure by reducing the amount of aqueous humor due to its production. It begins to act a third of an hour after instillation and continues for 24 hours. The maximum effect is observed after 1-2 hours.

When instilled, the medicine is quickly absorbed into the eyeball. The systemic effect is minimal and is carried out by absorption of Timolol through the conjunctiva, nasal mucosa, and lacrimal ducts.

Pharmacokinetics

When applied topically, it quickly penetrates the cornea and enters the systemic circulation in small quantities due to absorption through the vessels of the conjunctiva, mucous membranes of the nose and lacrimal tract.

Special instructions

Use with caution in patients with impaired liver function, kidney function, diabetes mellitus (especially labile course). With prolonged use, it increases the level of triglycerides in the blood plasma.

The safety and effectiveness of use in children have not been studied.

In ophthalmology, it is used for a long time, therefore, during the treatment period, the cornea should be examined at least once every 6 months, the function of tear secretion and the condition of the visual fields should be monitored.

Impact on the ability to drive vehicles and operate machinery

During the treatment period, you should refrain from engaging in potentially hazardous activities that require increased attention and rapid psychomotor reactions.

When used in ophthalmology immediately after instillation, a decrease in visual acuity and a slowdown in psychomotor reactions may occur, so you should refrain from engaging in potentially hazardous activities that require increased attention for 30 minutes.

Active ingredient

Timolol

Composition

The active component of the drug is timolol (timolol maleate), which contains 2.5 mg in 1 ml of solution.

Among the auxiliary components are:

preservative benzalkonium chloride (0.015),

betacyclodextrin,

water for injections,

Disodium EDTA,

disodium hydrogen phosphate dihydrate,

sodium chloride,

sodium dihydrogen phosphate dihydrate.

The solution itself is transparent, colorless or somewhat yellowish and does not have any mechanical inclusions.

Contraindications

The drug Okupres-E is not prescribed if there is an increased intolerance to the components of the drug. Also, you should not use it if you have a history of:

Bronchial asthma and other obstructive conditions.
Sinus bradycardia.
Deceleration of conduction through the atrioventricular connection of 2 and 3 degrees.
Presence of signs of serious heart failure.
Symptoms of cardiogenic shock.
Allergic manifestations that are accompanied by dermatological phenomena;
Severe atrophic rhinitis.
Dystrophic changes in corneal tissue.

Caution must be observed in cerebrovascular and heart failure, in patients with hypoglycemia, diabetes mellitus, thyrotoxicosis, myasthenia, in combination with systemic beta blockers.

The components of the drug Okupres-E are able to penetrate the placental bloodstream and into breast milk. In this regard, before prescribing the drug, it is necessary to evaluate the possible risks and potential benefits.

Side Effects

When using Okupres-E drops, both local and systemic manifestations may occur.

The first include: redness of the mucous membrane, corneal edema, burning, irritation, itching, photophobia, punctate keratopathy, lacrimation, diplopia, corneal hyposthesia, dryness, ptosis. In the case of operations against glaucoma (fistulizing), retinal detachment may form in the postoperative period.

Systemic reactions are similar to the side effects of all beta blockers (bronchospasm, heart failure, headache, etc.). Allergic reactions (eczema, urticaria) also sometimes occur.

The most dangerous is apnea, which occurs when the drug is prescribed to newborns.

Interaction

In case of an overdose of Okupres-E, general reactions to an overdose of beta blockers occur. In this case, you should rinse your eyes with saline solution or water and consult a doctor. Treatment is symptomatic.

Overdose

In case of an overdose of Okupres-E, general reactions to an overdose of beta blockers occur. In this case, you should rinse your eyes with saline solution or water and consult a doctor. Treatment is symptomatic.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25ºС.

Shelf life

2 years.

Manufacturer

Cadila Pharmaceuticals Ltd, India